# Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

> **NCT04055844** · PHASE2 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 14 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myeloid and Monocytic Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Ruxolitinib
- **DRUG:** Donor Lymphocyte Infusion (DLI)

## Key facts

- **NCT ID:** NCT04055844
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-17
- **Primary completion:** 2022-09-06
- **Final completion:** 2022-09-06
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04055844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04055844, "Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04055844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*